{
    "clinical_study": {
        "@rank": "124437", 
        "acronym": "ANTIBODY-RA", 
        "arm_group": [
            {
                "arm_group_label": "etanercept", 
                "description": "Participants currently receiving etanercept treatment in a clinical setting for a minimum of 6 months and maximum of 24 months prior to study assessment visit."
            }, 
            {
                "arm_group_label": "adalimumab", 
                "description": "Participants currently receiving adalimumab treatment in a clinical setting for a minimum of 6 months and maximum of 24 months prior to study assessment visit."
            }, 
            {
                "arm_group_label": "infliximab", 
                "description": "Participants currently receiving infliximab treatment in a clinical setting for a minimum of 6 months and maximum of 24 months prior to study assessment visit."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to examine the relationship between anti-drug antibodies, serum\n      drug concentrations, and clinical response for rheumatoid arthritis patients being treated\n      with etanercept, adalimumab or infliximab."
        }, 
        "brief_title": "Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "cross-sectional Population will be selected through convenience sampling.  Patients\n      sequentially visiting the rheumatology clinic for routine care who are receiving etanercept,\n      adalimumab, or infliximab for between 6 and 24 months will be evaluated for eligibility and\n      interest in participation.  A maximum of 200 patients per treatment will be enrolled."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age 18 years or older.\n\n          2. Diagnosis of RA based on the 1987 American College of Rheumatology revised criteria\n\n          3. Current continuous treatment with either etanercept, adalimumab, or infliximab for a\n             minimum of 6 months and maximum of 24 months.\n\n        Exclusion Criteria:\n\n          1. Treatment with biosimilar or investigational etanercept, adalimumab, or infliximab\n             within past 6 months.\n\n          2. Treatment with any other investigational drugs within past 3 months or five half\n             lives of the drug, whichever is longer.\n\n          3. Any medical condition that would interfere with rheumatoid arthritis evaluation or\n             other study assessments (eg, fibromyalgia, lupus)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Population will be selected from patients seen in a rheumatology clinical setting who\n        currently treated with etanercept, adalimumab or infliximab for rheumatoid arthritis"
            }
        }, 
        "enrollment": {
            "#text": "600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01981473", 
            "org_study_id": "B1801364"
        }, 
        "intervention": [
            {
                "arm_group_label": "etanercept", 
                "description": "N/A", 
                "intervention_name": "no intervention", 
                "intervention_type": "Other", 
                "other_name": "Enbrel"
            }, 
            {
                "arm_group_label": "adalimumab", 
                "description": "N/A", 
                "intervention_name": "no intervention", 
                "intervention_type": "Other", 
                "other_name": "Humira"
            }, 
            {
                "arm_group_label": "infliximab", 
                "description": "N/A", 
                "intervention_name": "no intervention", 
                "intervention_type": "Other", 
                "other_name": "Remicade"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "TNFR-Fc fusion protein", 
                "Infliximab", 
                "Adalimumab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "rheumatoid arthritis", 
            "etanercept", 
            "adalimumab", 
            "infiximab", 
            "anti-drug antibody", 
            "immunogenicity", 
            "drug concentration"
        ], 
        "lastchanged_date": "April 11, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1801364&StudyName=Drug%20Concentration%2C%20Immunogenicity%2C%20and%20Efficacy%20Study%20in%20Patients%20with%20Rheumatoid%20Arthritis%20Currently%20Treated%20with%20Etanercept%2C%20Adalimumab"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hot Springs", 
                        "country": "United States", 
                        "state": "Arkansas", 
                        "zip": "71913"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Covina", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91723"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brooklyn", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11235"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "3", 
        "official_title": "Anti-TNF Inhibitor Antibody-Mediated Blockade of Drug Efficacy in Rheumatoid Arthritis (ANTIBODY-RA)", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of Patients Positive for Antidrug Antibodies Among Those Treated with etanercept Versus Those Treated with Monoclonal Antibodies (adalimumab or infliximab)", 
            "safety_issue": "No", 
            "time_frame": "1 Day"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01981473"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "LDA is defined as a Disease Activity Score using 28 joint count (DAS28) of \u2264 3.2.  Patient DAS28 (ESR) score is calculated from the number of tender and swollen joints, erythrocyte sedimentation rate, and Subject General Health VAS assessment. Lower scores indicate better disease status.", 
                "measure": "Proportion of patients with Low Disease Activity (LDA)", 
                "safety_issue": "No", 
                "time_frame": "1 Day"
            }, 
            {
                "measure": "Concentration of Serotype-Specific Antibodies", 
                "safety_issue": "No", 
                "time_frame": "1 Day"
            }, 
            {
                "measure": "Proportion of Patients Positive for Antidrug Antibodies", 
                "safety_issue": "No", 
                "time_frame": "1 Day"
            }, 
            {
                "description": "CDAI is calculated from DAS28 prorated Swollen Joint Count (0-28) + DAS28 prorated Tender Joint Count (0-28) + Physician's Global Assessment (PGA) (0-10) + Subject's Global Assessment (0-10)", 
                "measure": "Clinical Disease Activity Index (CDAI) Scores", 
                "safety_issue": "No", 
                "time_frame": "1 Day"
            }, 
            {
                "description": "SDAI is calculated from DAS28 prorated Swollen Joint Count (0-28) + DAS28 prorated Tender Joint Count (0-28) + Physician's Global Assessment (PGA) (0-10) + Subject's Global Assessment (0-10) + c-reactive protein", 
                "measure": "Simplified Disease Activity Index (SDAI) Scores", 
                "safety_issue": "No", 
                "time_frame": "1 Day"
            }, 
            {
                "description": "DAS28 (ESR) score is calculated from the number of tender and swollen joints, erythrocyte sedimentation rate, and Subject General Health VAS assessment.", 
                "measure": "Disease Activity Score, 28 Joint Count, calculated with erythrocyte sedimentation rate (DAS28-ESR)", 
                "safety_issue": "No", 
                "time_frame": "1 Day"
            }, 
            {
                "description": "DAS28 (CRP) score is calculated from the number of tender and swollen joints, c-reactive protein, and Subject General Health VAS assessment.", 
                "measure": "Disease Activity Score, 28 Joint Count, calculated with c-reactive protein (DAS28-CRP)", 
                "safety_issue": "No", 
                "time_frame": "1 Day"
            }, 
            {
                "description": "HAQ-DI is a questionnaire that assesses the degree of difficulty a patient has experienced during the past week in dressing, grooming, arising, eating, walking, hygiene, reach, grip, and other activities.  Each question is answered with a level of difficulty score ranging from 0-3 with 0 representing \"no difficulty\" and 3 representing \"unable to do\".", 
                "measure": "Health Assessment Questionnaire (Disability and Discomfort Scales ) (HAQ-DI) Scores", 
                "safety_issue": "No", 
                "time_frame": "1 Day"
            }, 
            {
                "measure": "Spearman's Correlation Coefficient of Antidrug Antibody Titers with  DAS28-ESR", 
                "safety_issue": "No", 
                "time_frame": "1 Day"
            }, 
            {
                "measure": "Spearman's Correlation Coefficient of Antidrug Antibody Titers with DAS28-CRP", 
                "safety_issue": "No", 
                "time_frame": "1 Day"
            }, 
            {
                "measure": "Spearman's Correlation Coefficient of Antidrug Antibody Titers with CDAI", 
                "safety_issue": "No", 
                "time_frame": "1 Day"
            }, 
            {
                "measure": "Spearman's Correlation Coefficient of Antidrug Antibody Titers SDAI", 
                "safety_issue": "No", 
                "time_frame": "1 Day"
            }, 
            {
                "measure": "Spearman's Correlation Coefficient of Antidrug Antibody Titers with Trough Drug Concentration", 
                "safety_issue": "No", 
                "time_frame": "1 Day"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}